Level of instruction: Intermediate
Intended audience: This course is intended for molecular biology bench technicians and technologists, supervisors, and administrators.
Course description: This course covers some basic genetic principles as well as how changes to the genetic code can lead to carcinogenesis. The course also addresses how personalized medicine is aided by molecular diagnostics to match the patient with the correct targeted therapy.
Author information: Tabetha Sundin, PhD, HCLD (ABB), MB (ASCP)CM, has over 10 years of laboratory experience in cancer biology and clinical molecular diagnostics. She is the Scientific Director of Molecular Diagnostics and Serology at Sentara Healthcare. Dr. Sundin serves as a Speaker for AstraZeneca and Bristol-Myers Squibb covering multidisciplinary facilitation of biomarker testing in cancer patients. She is also an active member of the Association of Molecular Pathology (AMP) and involved with numerous efforts to support the molecular diagnostics field with American Medical Technologists (AMT) and Clinical & Laboratory Standards Institute (CLSI).
Reviewer information: Timothy Walls, M.D., M.S., is an AP/CP boarded pathologist. He has completed fellowships in medical microbiology as well as molecular genetic pathology. Currently he is the Director of Clinical Laboratories at Sentara Reference Laboratories. Timothy has earned his B.S. in Biochemistry, Cellular and Molecular Biology at the University of Tennessee, his M.S. in Forensic Science at Drexel University and his M.D. from the University of Tennessee Health Science Center.